ArticleFrontiers in molecular biosciences2025
Epigenetic dysregulation-induced metabolic reprogramming fuels tumor progression in bladder cancer.
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Mitochondrial vulnerability to aldehydic load and the role mitochondrial aldehyde dehydrogenases.Pharmacological research · 2026Review
- Identification of alpha1-oleate as a potent regulator of adipokine-dependent metabolism, in bladder cancer tissue.Cancer & metabolism · 2026Article
- Epigenetic Perspectives on Maternal Gut Microbiota's Impact on Embryonic and Fetal Development.Comprehensive Physiology · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bladder cancer remains a significant global health challenge with a high mortality rate despite advancements in treatment modalities. Metabolic alterations serve as crucial contributors to cancer progression, particularly influencing tumor aggressiveness and patient outcomes. Therefore, this study aimed to identify and characterize metabolic hubs associated with disease progression and tumor aggressiveness in bladder cancer. Methods: DNA methylation, mRNA expression and protein expression, along with clinical data for bladder cancer patients were retrieved from TCGA database. Differentially expressed metabolic hubs among tumor aggressiveness groups and between early vs advanced stage tumors were identified using ANOVA and Student's Results: Through a metabolism-targeted differential expression and survival analysis-based approach, we identified 105 metabolic genes, whose expression patterns correlated with tumor aggressiveness and clinical outcomes in bladder cancer patients. Subsequent network construction and random walk analysis refined this list to a seven-gene metabolic signature (Metab-GS), comprising both oncogenic (ALDH1B1, ALDH1L2, CHSY1, CSGALNACT2, GPX8) and tumor suppressors (FBP1, HPGD) hubs. Upstream analysis identified epigenetic modifications, particularly DNA hypermethylation of tumor suppressor metabolic hubs and reduced USF2-NuRD complex activity-driven increased expression of oncogenic metabolic hubs, contributing to glycolytic shift and extracellular matrix remodeling, and establishing an inflammatory tumor microenvironment. Lastly, validation of our findings in multiple independent GEO datasets confirmed that high Metab-GS scores are associated with tumor aggressiveness and progression, advanced disease stage, metastatic spread, disease recurrence, and poor overall and cancer-specific survival in bladder cancer patients. Conclusion: Overall, a seven-gene metabolic signature predicts tumor aggressiveness and poor prognosis in bladder cancer patients, underscoring the potential of targeting the epigenetic dysregulation-induced metabolic reprogramming as a therapeutic strategy for aggressive bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.